Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 2
2008 1
2009 1
2011 1
2013 3
2014 3
2016 3
2017 2
2018 5
2019 7
2020 8
2021 3
2022 7
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Salivary Duct Carcinoma"
Page 1
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, Hirai H, Yamada S, Kawakita D, Miura K, Kamata SE, Nagao T. Takahashi H, et al. J Clin Oncol. 2019 Jan 10;37(2):125-134. doi: 10.1200/JCO.18.00545. Epub 2018 Nov 19. J Clin Oncol. 2019. PMID: 30452336 Clinical Trial.
PURPOSE: Clinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease's rarity. ...The primary end point was the overall response rate; the secondary end points inclu …
PURPOSE: Clinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma …
Systemic therapy for salivary gland malignancy: current status and future perspectives.
Imamura Y, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ota I, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Yokota T, Okano S, Tanaka K, Onoe T, Ariizumi Y, Homma A. Imamura Y, et al. Jpn J Clin Oncol. 2022 Apr 6;52(4):293-302. doi: 10.1093/jjco/hyac008. Jpn J Clin Oncol. 2022. PMID: 35134985 Review.
Salivary gland malignancies are known as chemo-resistant tumors, which render optimal treatment challenging. ...Personalized therapies have become established options, particularly for androgen receptor-positive, HER2-positive and NTRK fusion-positive salivary gland …
Salivary gland malignancies are known as chemo-resistant tumors, which render optimal treatment challenging. ...Personalized therapie …
Postoperative Management of Salivary Gland Tumors.
Joshi NP, Broughman JR. Joshi NP, et al. Curr Treat Options Oncol. 2021 Feb 9;22(3):23. doi: 10.1007/s11864-021-00820-9. Curr Treat Options Oncol. 2021. PMID: 33560478 Review.
Both surgery and radiation may be utilized to address the lymph nodes at risk. This is especially important for minor salivary gland tumors. Radiation plays an important role in the adjuvant management of salivary gland tumors by reducing the risk of locoregional …
Both surgery and radiation may be utilized to address the lymph nodes at risk. This is especially important for minor salivary gland …
Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM, Lassche G, van Engen-van Grunsven ACH, Tada Y, Verhaegh GW, Schalken JA, Driessen CML, van Herpen CML. Uijen MJM, et al. Cancer Treat Rev. 2020 Sep;89:102069. doi: 10.1016/j.ctrv.2020.102069. Epub 2020 Jul 15. Cancer Treat Rev. 2020. PMID: 32717621 Free article.
BACKGROUND: Salivary duct carcinoma (SDC) is an aggressive subtype of salivary gland cancer. Approximately half of SDC patients will develop recurrences or metastases. Therapeutic palliative therapy is therefore often needed. ...
BACKGROUND: Salivary duct carcinoma (SDC) is an aggressive subtype of salivary gland cancer. Approximately half …
Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Jeong ISD, Moyers J, Thung I, Thinn MM. Jeong ISD, et al. Am J Case Rep. 2020 Jun 30;21:e925181. doi: 10.12659/AJCR.925181. Am J Case Rep. 2020. PMID: 32601266 Free PMC article.
BACKGROUND Salivary duct carcinoma (SDC) is a rare, aggressive head and neck cancer with frequent metastases. ...Combination chemotherapy with androgen deprivation for validation through clinical trials....
BACKGROUND Salivary duct carcinoma (SDC) is a rare, aggressive head and neck cancer with frequent metastases. ...Combin …
Parotid salivary duct carcinoma: a single institution's 20-year experience.
Stodulski D, Mikaszewski B, Majewska H, Kuczkowski J. Stodulski D, et al. Eur Arch Otorhinolaryngol. 2019 Jul;276(7):2031-2038. doi: 10.1007/s00405-019-05454-0. Epub 2019 May 6. Eur Arch Otorhinolaryngol. 2019. PMID: 31062093 Free PMC article.
PURPOSE: The aim of the study was to assess the treatment results of the parotid gland salivary duct carcinoma (SDC). MATERIAL AND METHODS: A retrospective clinicopathological analysis of 40 patients treated for parotid SDC in 1996-2015 was performed. ...CONC …
PURPOSE: The aim of the study was to assess the treatment results of the parotid gland salivary duct carcinoma (SDC). M …
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W, Verhaegh GW, van Engen-van Grunsven IA, van Strijp D, Kroeze LI, Ligtenberg MJ, van Zon HB, Hendriksen Y, Keizer D, van de Stolpe A, Schalken JA, van Herpen CM. van Boxtel W, et al. Int J Cancer. 2020 Jun 1;146(11):3196-3206. doi: 10.1002/ijc.32795. Epub 2019 Dec 12. Int J Cancer. 2020. PMID: 31745978 Free PMC article.
Androgen deprivation therapy (ADT) is first-line palliative treatment in androgen receptor-positive (AR+) salivary duct carcinoma (SDC), and response rates are 17.6-50.0%. We investigated potential primary ADT resistance mechanisms for their predictive value …
Androgen deprivation therapy (ADT) is first-line palliative treatment in androgen receptor-positive (AR+) salivary duct car …
Targeting human EGFR 2 (HER2) in salivary gland carcinoma.
Wotman M, El-Naggar A, Ferrarotto R. Wotman M, et al. Expert Rev Anticancer Ther. 2023 Jun;23(6):573-582. doi: 10.1080/14737140.2023.2208350. Epub 2023 May 16. Expert Rev Anticancer Ther. 2023. PMID: 37114470
INTRODUCTION: Human epidermal growth factor receptor 2 (HER2) protein overexpression, gene amplification, and activating mutations have been identified in a subset of salivary gland carcinoma (SGC) histologies (HER2-positive), especially in salivary duct …
INTRODUCTION: Human epidermal growth factor receptor 2 (HER2) protein overexpression, gene amplification, and activating mutations have been …
Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study.
Okada T, Saotome T, Nagao T, Masubuchi T, Fushimi C, Matsuki T, Takahashi H, Miura K, Tsukahara K, Tada Y. Okada T, et al. In Vivo. 2019 May-Jun;33(3):843-853. doi: 10.21873/invivo.11549. In Vivo. 2019. PMID: 31028207 Free PMC article.
BACKGROUND/AIM: The aim of this study was to evaluate the efficacy and safety of carboplatin/docetaxel combination therapy in patients with locally advanced and/or recurrent/metastatic (LA/RM) salivary gland carcinoma (SGC). MATERIALS AND METHODS: This was a …
BACKGROUND/AIM: The aim of this study was to evaluate the efficacy and safety of carboplatin/docetaxel combination therapy in patients with …
Near-infrared photoimmunotherapy for salivary duct carcinoma.
Makino T, Sato Y, Uraguchi K, Naoi Y, Fukuda Y, Ando M. Makino T, et al. Auris Nasus Larynx. 2024 Apr;51(2):323-327. doi: 10.1016/j.anl.2023.09.006. Epub 2023 Sep 27. Auris Nasus Larynx. 2024. PMID: 37775468
In Japan, near-infrared photoimmunotherapy (NIR-PIT) was introduced in 2021 as a treatment option for unresectable recurrent head and neck cancer. The treatment targets the epidermal growth factor receptor (EGFR), which is overexpressed in 80-90 % of head and neck squamous …
In Japan, near-infrared photoimmunotherapy (NIR-PIT) was introduced in 2021 as a treatment option for unresectable recurrent head and …
44 results